Increlex for growth failure in children

Ipsen has launched Increlex (mecasermin) for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-1 (IGF-1) deficiency.

PHARMACOLOGY
Mecasermin is a human IGF-1 produced by recombinant DNA technology.

IGF–1 is the principal hormonal mediator of growth. In target tissues, IGF–1 activates the IGF–1 receptor, leading to intracellular signalling to induce and support statural growth. IGF–1 induces the uptake of glucose, fatty acids and amino acids so that metabolism supports growing tissues.

Further information: Ipsen 01753 627777

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Compare COVID-19 vaccines with new MIMS table

Compare COVID-19 vaccines with new MIMS table

Key characteristics of available COVID-19 vaccines...

Deleted products - live tracker

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...